The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3487-3489

  Pfister, David G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

ASSERTIVENESS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; FEBRILE NEUTROPENIA; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CANCER; MEDICAL DECISION MAKING; MELANOMA; ONCOLOGIST; OVERALL SURVIVAL; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SOLID TUMOR; ECONOMICS; NEOPLASMS; TRENDS; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS; DRUG COSTS; HUMANS; NEOPLASMS;

EID: 84891544805     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3466     Document Type: Review

References (33)

1. Drugs approved for kidney (renal cell) cancer. htpp//www.cancer.gov/ cancertopics/druginfo/kidneycancer
2. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
3. Miksad RA, Schnipper L, Goldstein M: Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25:4506-4508, 2007
4. Kantarjian HM, Fojo T, Mathisen M, et al: Cancer drugs in the United States: Justum pretium-The just price. J Clin Oncol 31:3600-3604, 2013
5. REDBOOK Online. Greenwood Village, CO, Thomson Reuters (Healthcare) Inc. http://www.redbook.com/redbook/online/
6. Bach P, Saltz L, Wittes R: In cancer care, cost matters. New York Times, October 15, 2012:A25
7. Pollack A: Cancer specialists attack high drug costs. New York Times, April 26, 2013:B1,4
8. VanLare JM, Conway PH: Value-based purchasing: National programs to move from volume to value. N Engl J Med 364:292-295, 2012
9. Merck offers free distribution of new river blindness drug. New York Times, October 22, 1987. http//www.nytimes.com/10/22/world/merck-offersfree- distribution-of-new-river-blindness-drug/htm
10. Smith TJ, Hillner BE: Bending the cost curve in cancer care. N Engl J Med 364:2060-2065, 2011
11. Elkin EB, Bach PB: Cancer's next frontier: Addressing high and increasing costs. JAMA 303:1086-1087, 2010
12. Schrag D, Hanger M: Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey. J Clin Oncol 25:233-237, 2007
13. Himmelstein D, Thorne D, Warren E, et al: Medical bankruptcy in the United States, 2007: Results of a national study. Am J Med 122:741-746, 2009
14. Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381-390, 2013
15. Jacobson M, Earle CC, Price M, et al: How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) 29:1391-1399, 2010
16. Weight CJ, Klein EA, Jones JS: Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the US Medicare population. Cancer 112:2195-2201, 2008
17. Potosky AL, Malin JL, Kim B, et al: Use of colony-stimulating factors with chemotherapy: Opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103:979-982, 2011
18. Neumann PJ, Palmer JA, Nadler E, et al: Cancer therapy costs influence treatment: A national survey of oncologists. Health Aff (Millwood) 29:196-202, 2010
19. McFarlane J, Riggens R, Smith TJ: SPIKE$: A six-step protocol for delivering bad news about the cost of medical care. J Clin Oncol 26:4200-4204, 2008
20. Merepol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
21. Mason A, Drummond M, Ramsey S, et al: Comparison of anticancer drug coverage decisions in the United States and United Kingdom. Does the evidence support the rhetoric? J Clin Oncol 3234-3238, 2010
22. Levy AR, Mitton C, Johnson KM, et al: International comparison of comparative effectiveness research in five jurisdictions: Insights for the US. Pharmacoeconomics 28:813-830, 2010
23. Clement FM, Harris A, Li JJ, et al: Using effectiveness and costeffectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada. JAMA 302:1437-1443, 2009
24. Pearson SD, Bach PB: How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Heal Aff (Millwood) 29:1796-1804, 2010
25. Weinstein MD, Skinner JA: Comparative effectiveness and health care spending: Iimplications for reform. N Engl J Med 362:460-465, 2010
26. The National Comprehensive Cancer Network, The US Oncology Network and McKesson Specialty Health collaborate to offer new Value Pathways for cancer care. http://www.nccn.org/about/news/newsinfo.asp?NewsID-327
27. Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 291:2720-2726, 2004
28. Link MP: Collaborating to conquer cancer: Lessons from our children. J Clin Oncol 31:825-832, 2013
29. Brody H: Medicine's ethical responsibility for health care reform: The Top Five list. N Engl J Med 362:283-285, 2010
30. Schnipper LE, Smith TJ, Rhagavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The Top Five list for oncology. J Clin Oncol 30:1715-1724, 2012
31. Wong Y-N: Are oncologists' financial incentives aligned with quality of care? J Clin Oncol 31:517-519, 2013
32. Bach PB, Mirkin JN, Luke JJ: Episode-based payment for cancer care: A proposed pilot for Medicare. Health Aff (Millwood) 30:500-509, 2011
33. Malin JL: Wresting with the high price of cancer care: Should we control costs by individuals' ability to pay or society's willingness to pay? J Clin Oncol 28:3212-3214, 2010